Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: An open label phase II study

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 441-448

  Tsavaris, N ^a   Kosmas, Christos ^a,b   Skopelitis, H ^a   Dimitrakopoulos, A ^a   Kopteridis, P ^a   Bougas, D ^a   Stravodimos, K ^a   Mitropoulos, D ^a   Alamanis, C ^a   Giannopoulos, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

Advanced bladder cancer; Chemotherapy; Epirubicin; Methotrexate; Paclitaxel; Vinblastine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 24644512285     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.444     Document Type: Article

References (34)

1. Otto T, Bex A, Krege S, Walz PH, Rubben H. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (Ml). A clinical phase II study. Cancer 1987; 80: 465-470.
2. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-469.
3. Logothetis CJ, Dexeus FH, Chong C, et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy in unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989; 141: 33-37.
4. Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer 1980; 45: 1879-1888.
5. Loehrer PJ, Einhorn LH, Elson PH, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
6. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide, doxorubicin and cisplatin for patients with locally advanced uro-thelial tumors with or without nodal metastases. J Urol 1985; 134: 460-464.
7. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-407.
8. Witjes JA, Wullink M, Oosterhof GON, de Mulder P. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 1997; 131: 414-419.
9. Harker WG, Meyers FJ, Freiha FS, et al. for the Northern California Oncology Group Study. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol 1985; 13: 1463-1470.
10. Skarlos DV, Aravantinos G, Linardou H, et al. for the Hellenic Co-operative Oncology Group Study: Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. Eur Urol 1997; 31: 420-427.
11. McGuire WP, Rowinsky E, Rosenheim NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-279.
12. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 1797-1805.
13. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 384-388.
14. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 1994; 12: 2264-2270.
15. Pycha A, Grbovic M, Posch B, et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary track. Urology 1999; 53: 511-515.
16. Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J. A feasibility study of one hour paclitaxel infusion in solid tumors. Cancer Chemother Pharmacol 1997; 40: 353-357.
17. Tsavaris N, Kosmas C. Risk of severe acute hypersensitivity reactions after rapid (less than 1 hour) paclitaxel infusion. Cancer Chemother Pharmacol 1998; 42: 509-511.
18. Calvert AH, Newell DR, Gumbell LA. Carboplatin dosage: prospective evaluation of a simple formula on renal function. J Clin Oncol 1989; 7: 1748-1756.
19. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-217.
20. Kaplan EL, Meier P. Non parametric estimation for incomplete observations J Am Stat Assoc 1958; 53: 457-481.
21. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
22. Saxman S, Propert K, Einhorn L, et al. Long term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
23. Sousa-Escandon A, Vazquez S, Quintero-Aldana G, et al. Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial. Int J Urol 2002; 9: 162-166.
24. Vaughn DJ. Paclitaxel and carboplatin in bladder cancer: recent developments. Eur J Cancer 2000; 36: 7-12 (Suppl 2).
25. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-940.
26. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002; 95: 1022-1027.
27. Bamias A, Aravantinos G, Deliveliotis C, et al. and Hellenic Cooperative Oncology Group. Docetaxel and cis-platin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-228.
28. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Candour-Edwards R, deVere White RW. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000; 55: 521-525.
29. Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Br J Cancer 2000; 83: 1612-1616.
30. Bellmunt J, Cos J, Cleries R, et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002; 20: 673-685.
31. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23: 1185-1191.
32. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-2533.
33. Hoshi S, Ohyama C, Ono K, et al. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. Int J Clin Oncol 2004; 9: 125-129.
34. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639-1645.